NOS2 and neoplasm: Chemotherapeutic treatment via docetaxel reduces MDSC Arg1 and iNOS activity showing comparable efficacy to pharmacological inhibition of both Arg1 and iNOS, which in turn releases the inhibition on T cells allowing anti-tumour effector function [68].